[Correction of hyperdyslipidemia using polyene-structure substances. Controlled clinical trial].

Mepartricin (SPA-S-160 enteric-coated tablets) fat-lowering effect was evaluated in 20 patients with lipids disorders of various type. The cross-over trial was carried out with clofibrate as reference drug. Posology consisted, in both treatments, of 3 tablets/die. All subjects received each drug for a 30-day period, with a drug-free interval of 30 days. The results proved positive for both drugs but mepartricin showed a better therapeutical index. Local and systemic tolerance was good for both drugs even though the transaminases values were found to be sensibly higher after the therapeutic cycle with clofibrate.